Health Condition 1: H00-H59- Diseases of the eye and adnexa
Conditions
Interventions
Intervention1: Intravitreal Razumab: Razumab is an intravitreal antivascular endothelial growth factor injected intravitreally for reducing macular edema. 0.5mg of Razumab in 0.05ml will be injected i
Sponsors
ESIC postgraduate institute of medical science and research
Eligibility
Inclusion criteria
Inclusion criteria: patients with diabetic macular edema or macular edema due to retinal vaso-occlussive disease with central macular thickness of less or equal to 315 micron and visual acuity of less or equal to 0.2 on LogMAR chart will be included in the study.
Exclusion criteria
Exclusion criteria: 1. pre existing macular scar or dystrophy. 2.patients with active inflammatory and infectious diseases of the eye. 3. Patients already under treatment for macular edema in other hospital. 4.patients with history of recent ocular history or trauma. 5. patients with history of cerebrovascular or cardiovascular comorbidities.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.the percentage of reduction of macular edema after 4 weeks. Timepoint: 1.the percentage of reduction of macular edema after 4 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| improvement in best corrected visual acuity after 4 weeks of injection of intravitreal RazumabTimepoint: 1.visual acuity and macular edema will be measured before the intravitreal antivegf injection. 2. 1 week later, intraocular pressure is measured to rule out side effects. 3. 1 month after the injection, visual acuity and macular edema will be re- assessed. | — |
Countries
India
Contacts
Public ContactMalathi VK
ESIC postgraduate institute of medical science and research
Outcome results
None listed